Call Today: 800-417-9951
Contact us for free information or to start a free case review.
AvandiaŽ class action lawsuits are cases in which multiple plaintiffs with similar injuries pool their legal claims and attempt to recover compensation from GlaxoSmithKline, the maker of AvandiaŽ medication.
First approved by the FDA in 1999, AvandiaŽ is an oral medication used in the treatment of type-2 diabetes and NOT indicated for treatment of type-1 diabetes. AvandiaŽ comes in pill-form and is generally prescribed to be taken in the morning and evening (with or without food).
However, while this medication is able to improve control over blood glucose levels, it has been found to cause a range of severe health complications, including (but not limited to) heart attack, severe allergic reaction and liver dysfunction.
Consequently, it's essential that diabetes patients:
In May 2007, a critical AvandiaŽ study published in the medical journal known as Heart suggested that:
Although no national AvandiaŽ recall was issued at the time FDA did vote to require GlaxoSmithKline to include black box warnings on AvandiaŽ packaging. A number of AvandiaŽ class action lawsuits were filed in an effort to compensate patients seriously injured after taking this medication.
When it comes to obtaining an AvandiaŽ settlement, injured parties have a choice to file an individual AvandiaŽ lawsuit or join an already-progressing class action lawsuit. An AvandiaŽ class action lawsuit is most appropriate for plaintiffs who:
Injured AvandiaŽ patients can get a thorough evaluation of their cases, as well as expert advice regarding the best choices for their situation, during a free initial consultation.
Plaintiffs who choose to be represented by experienced, professional AvandiaŽ class action lawyers will benefit from:
For more information about the current AvandiaŽ class action lawsuits, contact us today.
The FDA announced that is has made a change regarding cardiovascular risks to the Avandia® (rosiglitazone) label and patient Medication Guide, Feb. 4, 2011.
The FDA announcement also said that Avandia®'s drug label was updated ...
A government run diabetes trial was halted 18 months early after a safety analysis revealed an increased risk of death in patients whose blood sugar levels dipped too low.
The 10,000 patient trial was examining the effectiveness of aggressive ...
A new study published in the Journal of the American Medical Association reaffirms previous findings about the diabetes drug Avandia—that is, it carries a significantly increased risk of heart failure, heart attack, and death.
Ob...
Copyright Š 2001 - 2012 Online Lawyer Source | Legal Marketing Site Designed by eJustice
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.